The Hydropothecary Corporation is a buy, says Echelon Wealth

Gatineau, Quebec’s The Hydropothecary Corporation (TSXV:THCX) gets a 12-month target price increase from Echelon Wealth Partners’ Russell Stanley, who sees the licensed cannabis producer to be trading at a discount to its peer group of cannabis companies.

On Thursday, the analyst’s research update reiterated his “Speculative Buy” rating with a new target of $6.75 (up from $5.50).

Attending the Hydropothecary Corp.’s Investor Day in New York City on Wednesday, Stanley says the key takeaway was that the company expects dried cannabis to eventually be commoditized, and thus that the real money will be in consumer packaged goods.

The analyst agrees with this premise.

“Management’s overall goal is to become a consumer packaged goods (CPG) company with 35-40 per cent EBITDA margins, with straight cultivation operating margins likely trending to the mid-single digit range over time as supply increases,” he says.

“Geographically, management views its penetration of the Québec market as the beachhead for its expansion into other provinces, predominantly to the west. Once the Company’s position in Canada has been strengthened, and adult-use is legalized in other markets, international expansion becomes a bigger priority,” says Stanley.

Stanley asserts that THCX is second only to Canopy Growth Corp in terms of aggregate sales commitments but that relative to its capacity plans (108,000 kg of dried cannabis annually), the Hydropothecary has pre-sold more of its production than any other licensed producer.

The analyst says that potential catalysts going forward include supply contract developments, expansion progress updates, product development news, a TSX graduation and improved financial results. The analyst also notes that THCX’s fully-funded capacity expansion plans and sales visibility make it an attractive M&A candidate.

The $6.75 target price comes from a 19x C2019 EBITDA estimate valuation multiple and represents a projected return of 33 per cent at the time of publication.

Tagged with: thcx
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

This Canadian microcap tech stock has massive upside, analyst says

Research Capital analyst Greg McLeish reiterated his “Speculative Buy” rating and $3.00 target on The FUTR Corporation (The FUTR Corporation… [Read More]

9 hours ago

Should you sell your BRP stock?

TD Cowen analyst Brian Morrison downgraded BRP  (BRP Stock Quote, Chart, News, Analysts, Financials TSX:DOO) to “Hold” from “Buy” and… [Read More]

14 hours ago

Constellation Software is “misunderstood” right now, this investor says

In an appearance on BNN Bloomberg Market Call on April 14, Raymond James Investment Counsel portfolio manager Chris Blumas said… [Read More]

15 hours ago

Buy MDA Space? Here’s what this analyst thinks

Beacon analyst Russell Stanley maintained his “Buy” rating on MDA Space (MDA Space Stock Quote, Chart, News, Analysts, Financials TSX:MDA)… [Read More]

18 hours ago

Merlin Labs is undervalued, this analyst says

Roth Capital Markets initiated coverage of Merlin Labs (Merlin Labs Stock Quote, Chart, News, Analysts, Financials NASDAQ:MRLN) with a “Buy”… [Read More]

19 hours ago

Acumen Capital likes NeuPath Health right now

Acumen Capital analyst Nick Corcoran has initiated coverage of NeuPath Health (NeuPath Health Stock Quote, Chart, News, Analysts, Financials TSXV:NPTH)… [Read More]

2 days ago